175 related articles for article (PubMed ID: 16100900)
1. [Binding of alpha-2-antiplasmin with fibrinogen/fibrin and their fragments independent of factor XIII].
Zadorozhna MB; Hrynenko TV; Iusova OI; Volkov HL
Ukr Biokhim Zh (1999); 2004; 76(5):71-7. PubMed ID: 16100900
[TBL] [Abstract][Full Text] [Related]
2. [Inhibition of the process of Glu-plasminogen activation by tissue activator with fibrin, DDE-complex, and D-dimer using alpha-2-antiplasmin].
Hrynenko TV; Zadorozhna MB; Platonova TM; Volkov HL
Ukr Biokhim Zh (1999); 2005; 77(5):45-51. PubMed ID: 16846069
[TBL] [Abstract][Full Text] [Related]
3. [Regulation with alpha-2-antiplasmin of Glu-plasminogen activation by tissue activator on fibrin].
Hrynenko TV; Zadorozhna MB; Iusova OI
Ukr Biokhim Zh (1999); 2006; 78(3):106-12. PubMed ID: 17100317
[TBL] [Abstract][Full Text] [Related]
4. The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin.
Rouy D; Anglés-Cano E
Biochem J; 1990 Oct; 271(1):51-7. PubMed ID: 1699517
[TBL] [Abstract][Full Text] [Related]
5. Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites.
Tsurupa G; Yakovlev S; McKee P; Medved L
Biochemistry; 2010 Sep; 49(35):7643-51. PubMed ID: 20687529
[TBL] [Abstract][Full Text] [Related]
6. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
[TBL] [Abstract][Full Text] [Related]
7. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
[TBL] [Abstract][Full Text] [Related]
8. Cross-linking of plasminogen activator inhibitor 2 and alpha 2-antiplasmin to fibrin(ogen).
Ritchie H; Lawrie LC; Crombie PW; Mosesson MW; Booth NA
J Biol Chem; 2000 Aug; 275(32):24915-20. PubMed ID: 10816585
[TBL] [Abstract][Full Text] [Related]
9. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
10. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin.
Reed GL; Matsueda GR; Haber E
Thromb Haemost; 1992 Sep; 68(3):315-20. PubMed ID: 1279832
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase.
Collen D; Van Hoef B; Schlott B; Hartmann M; Gührs KH; Lijnen HR
Eur J Biochem; 1993 Aug; 216(1):307-14. PubMed ID: 7689966
[TBL] [Abstract][Full Text] [Related]
12. Effects of fibrin and alpha2-antiplasmin on plasminogen activation by staphylokinase.
Okada K; Ueshima S; Takaishi T; Yuasa H; Fukao H; Matsuo O
Am J Hematol; 1996 Nov; 53(3):151-7. PubMed ID: 8895684
[TBL] [Abstract][Full Text] [Related]
13. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
Hare TR; Gardell SJ
Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
[TBL] [Abstract][Full Text] [Related]
14. On the molecular interactions between plasminogen-staphylokinase, alpha 2-antiplasmin and fibrin.
Lijnen HR; Van Hoef B; Matsuo O; Collen D
Biochim Biophys Acta; 1992 Jan; 1118(2):144-8. PubMed ID: 1730031
[TBL] [Abstract][Full Text] [Related]
15. Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.
Weitz JI; Leslie B; Hirsh J; Klement P
J Clin Invest; 1993 Apr; 91(4):1343-50. PubMed ID: 7682569
[TBL] [Abstract][Full Text] [Related]
16. Fibrinogen and fibrin structure and functions.
Mosesson MW
J Thromb Haemost; 2005 Aug; 3(8):1894-904. PubMed ID: 16102057
[TBL] [Abstract][Full Text] [Related]
17. Conversion of fibrinogen to fibrin: mechanism of exposure of tPA- and plasminogen-binding sites.
Yakovlev S; Makogonenko E; Kurochkina N; Nieuwenhuizen W; Ingham K; Medved L
Biochemistry; 2000 Dec; 39(51):15730-41. PubMed ID: 11123898
[TBL] [Abstract][Full Text] [Related]
18. Analysis of fibrin formation and proteolysis during intravenous administration of ancrod.
Dempfle CE; Argiriou S; Kucher K; Müller-Peltzer H; Rübsamen K; Heene DL
Blood; 2000 Oct; 96(8):2793-802. PubMed ID: 11023513
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the factors contributing to fibrin-dependent plasminogen activation.
Mosesson MW; Siebenlist KR; Voskuilen M; Nieuwenhuizen W
Thromb Haemost; 1998 Apr; 79(4):796-801. PubMed ID: 9569195
[TBL] [Abstract][Full Text] [Related]
20. Effect of fibrin degradation products on fibrinolytic process.
Yatsenko TA; Rybachuk VM; Yusova OI; Kharchenko SM; Grinenko TV
Ukr Biochem J; 2016; 88(2):16-24. PubMed ID: 29227597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
